Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Integrating trans-omics, cellular experiments and clinical validation to identify ILF2 as a diagnostic serum biomarker and therapeutic target in gastric cancer

Fig. 4

Bioinformatics analyses of ILF2 in gastric cancer. *P < 0.05, **P < 0.01, ***P < 0.001. A-C: Comparison of immune checkpoint-related gene expression levels between the high and low expression groups of biomarkers. D-G: Comparison of sensitivity to anticancer drugs between the high and low ILF2 expression groups. H-K: Comparison of response to immunotherapy between the high and low ILF2 expression groups; IPS, the Immunophenoscore; POS, positive; NEG, negative

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us